Lexaria Bioscience Corp. (Nasdaq: LEXX) announced on June 25, 2026, that dosing has begun in Human Pilot Study #7 (GLP-1-H26-7), a 5-week trial evaluating two oral DehydraTECH-semaglutide (DHT-sema) compositions against Novo Nordisk's commercially available Wegovy tablets. The study, which started on June 14th, seeks to preserve the superior safety and tolerability profiles observed in previous Lexaria GLP-1 studies while achieving pharmacokinetic performance matching or exceeding the Wegovy control.
This study marks a significant step for Lexaria as it explores new enhancements to its DehydraTECH drug delivery platform. For the first time, Lexaria will use an oral tablet DHT-sema composition, mimicking the physical properties of Novo's Rybelsus and Wegovy SNAC-inclusive tablets. Additionally, both the tablet and capsule test articles will be formulated with salcaprozate sodium (SNAC), a key absorption enhancer, and evaluated over multiple doses for the first time. Previous single-dose studies (GLP-1-H24-1 and GLP-1-H24-2) demonstrated promising results, and this 5-week duration is designed to achieve steady-state concentration levels.
The study comprises three arms comparing SNAC-inclusive DHT-sema in tablet and capsule formats to Wegovy tablets, all under fasted conditions consistent with Novo's oral semaglutide administration guidelines. Lexaria expects the results to attract attention from the pharmaceutical industry, potentially leading to commercial partnerships focused on its DehydraTECH technology. The company believes that successful outcomes could offer an oral alternative with improved safety and tolerability, addressing a key need in the growing GLP-1 receptor agonist market.
The implications for the industry are substantial. Oral semaglutide drugs like Wegovy and Rybelsus have transformed diabetes and obesity treatment, but gastrointestinal side effects remain a concern. Lexaria's DehydraTECH platform aims to reduce these side effects while maintaining efficacy, which could broaden patient adherence and market penetration. If the study succeeds, it could position Lexaria as a key partner for pharmaceutical companies seeking to enhance their oral GLP-1 formulations.
The study is fully funded from existing corporate resources. Lexaria holds a robust intellectual property portfolio with 66 patents granted and pending applications worldwide. The company's DehydraTECH technology has repeatedly shown the ability to increase bio-absorption and reduce side effects for a variety of drugs.
Lexaria's results will be closely monitored by industry observers and potential collaborators. The company's ability to match or exceed the performance of established products like Wegovy could unlock significant commercial opportunities in the rapidly expanding GLP-1 market, projected to reach $100 billion annually by 2030.
